The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...

The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the treatment of adults with KRAS-mutated, recurrent low-grade serous ovarian ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

Verastem Oncology (NASDAQ:VSTM) has received FDA orphan drug designation for its drug candidate avutometinib for the treatment of a rare cancer. The orphan drug status was assigned to avutometinib, a ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced new results from the first-ever ...

Verastem Oncology Inc. CEO Dan Paterson said he is “not expecting a huge bolus [of ovarian cancer patients] at the beginning” of Avmapki/Fakzynja’s launch, but momentum will build over time. “Based on ...

An ovarian cancer survivor has won a global award for her charity fundraising work. Diane Boothby, from Downham, received her ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...